Agilent Technologies Inc (NYSE:A) Shares Bought by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. boosted its stake in shares of Agilent Technologies Inc (NYSE:A) by 67.3% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 39,871 shares of the medical research company’s stock after purchasing an additional 16,041 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Agilent Technologies were worth $3,056,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in A. Invesco Ltd. boosted its stake in Agilent Technologies by 478.4% during the second quarter. Invesco Ltd. now owns 9,230,526 shares of the medical research company’s stock worth $689,243,000 after buying an additional 7,634,621 shares during the last quarter. Nuveen Asset Management LLC raised its position in Agilent Technologies by 1,283.4% in the second quarter. Nuveen Asset Management LLC now owns 1,792,959 shares of the medical research company’s stock valued at $133,880,000 after purchasing an additional 1,663,354 shares during the period. Findlay Park Partners LLP raised its position in Agilent Technologies by 51.9% in the second quarter. Findlay Park Partners LLP now owns 4,500,000 shares of the medical research company’s stock valued at $336,015,000 after purchasing an additional 1,538,234 shares during the period. D. E. Shaw & Co. Inc. raised its position in Agilent Technologies by 40.8% in the second quarter. D. E. Shaw & Co. Inc. now owns 4,910,795 shares of the medical research company’s stock valued at $366,689,000 after purchasing an additional 1,423,567 shares during the period. Finally, Impax Asset Management Group plc raised its position in Agilent Technologies by 26.7% in the second quarter. Impax Asset Management Group plc now owns 3,166,667 shares of the medical research company’s stock valued at $236,455,000 after purchasing an additional 667,383 shares during the period.

A stock opened at $76.64 on Friday. The company has a current ratio of 2.13, a quick ratio of 1.72 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $23.38 billion, a PE ratio of 27.47, a P/E/G ratio of 1.88 and a beta of 1.42. Agilent Technologies Inc has a 12-month low of $62.00 and a 12-month high of $82.27. The business’s fifty day moving average price is $75.70 and its 200 day moving average price is $72.83.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, August 14th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.72 by $0.04. The firm had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.24 billion. Agilent Technologies had a return on equity of 20.00% and a net margin of 21.06%. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.67 EPS. Research analysts predict that Agilent Technologies Inc will post 3.08 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 23rd. Investors of record on Tuesday, October 1st were issued a $0.164 dividend. The ex-dividend date was Monday, September 30th. This represents a $0.66 annualized dividend and a dividend yield of 0.86%. Agilent Technologies’s dividend payout ratio is presently 23.66%.

A number of equities research analysts have commented on A shares. Zacks Investment Research downgraded Agilent Technologies from a “buy” rating to a “hold” rating and set a $75.00 target price on the stock. in a research report on Monday, August 19th. Bank of America downgraded Agilent Technologies from a “buy” rating to a “neutral” rating and set a $76.00 target price on the stock. in a research report on Tuesday, July 16th. Piper Jaffray Companies lifted their target price on Agilent Technologies from $83.00 to $86.00 and gave the company an “overweight” rating in a research report on Thursday, August 15th. UBS Group downgraded Agilent Technologies from a “buy” rating to a “neutral” rating and set a $82.00 target price on the stock. in a research report on Friday, October 18th. Finally, Needham & Company LLC lifted their target price on Agilent Technologies to $92.00 and gave the company a “buy” rating in a research report on Monday, August 19th. Seven investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $84.00.

In related news, CEO Michael R. Mcmullen sold 24,635 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $77.50, for a total value of $1,909,212.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Heidi Fields sold 4,000 shares of the business’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $78.56, for a total value of $314,240.00. Following the completion of the sale, the director now owns 53,287 shares in the company, valued at approximately $4,186,226.72. The disclosure for this sale can be found here. Insiders sold a total of 32,635 shares of company stock worth $2,507,293 in the last quarter.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Further Reading: How to trade on quiet period expirations

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.